Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Daytrading Canadian stocks in Realtime -- Ignore unavailable to you. Want to Upgrade?

To: Rocket Red who wrote (53339)	8/30/2001 1:38:19 PM
From: bigbuk	Read Replies (3) \| Respond to of 62347

seems other s may be paid by others <ggggg> MEDC did you get your borrws at 28s? :)

To: Rocket Red who wrote (53339)	9/2/2001 9:47:16 PM
From: bigbuk	Read Replies (1) \| Respond to of 62347

VERY BIG GRIN :)))))))))))))))) love those gapdowns-- hope iright :))) Using a competitor's analysis, Alan Abelson of Barron's took aim at Med-Design Corp. (MEDC: news, chart, profile) over the weekend, praising the CEO of Retractable Technologies (RVP: news, chart, profile) for his critique of Wall Street's kind treatment of his rival. Thomas Shaw, Abelson wrote, aptly pointed that much of the fuss over Med-Design is tied to the company's patents for various automated retraction syringes -- including technologies that have tenuous sales prospects at best. And even if they do make it to market, Shaw said, slow FDA approval and limited patent life will generate only a small fraction of the tens of millions they have helped tack on to the company's market cap. Shares in Med-Design closed down $1.90, or better than 7 percent, to $23.70 Friday while Retractable tacked on 20 cents to $4.90.